Anti-IL-33 (mouse) (Mouse) mAb

MBL
Product Code: MBL-M187-3
Product Group: Primary Antibodies
Supplier: MBL
CodeSizePrice
MBL-M187-3200 ul£507.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1 κ
Antibody Clonality: Monoclonal
Antibody Clone: 1F11
Regulatory Status: RUO
Target Species: Mouse
Application: Western Blot (WB)
Shipping:
4°C
Storage:
4°C

Images

1 / 1

Documents

Further Information

Applications:
WB - 1 ug/mL (chemiluminescence detection system)
Background:
Interleukin-1 (IL-1) family, such as IL-1α/β and IL-18, has important functions in host defense, autoimmune disease and inflammation. IL-33, a member of the IL-1 family of cytokine, is a ligand for the IL-1 receptor families ST2 (IL-33Rα chain) and IL-1RAcP, which induces the production of Th2-associated cytokines from mast cells and basophils. IL-33/ST2 signaling results in activation of NF-κB or AP-1 induces Th2 associated cytokines, IL-4, IL-5 and IL-13. IL-33 is also described as a Nuclear Factor from High Endothelial Venules (NF-HEV) and as DVS27. IL-33 is localized in the nucleus of human endothelial and epithelial cells that binds to chromatin via a homeodomain and nuclear localization signal in its N-terminus. IL-33 is a dual functional protein that may function as both a proinflammatory cytokine and a nuclear factor with transcriptional regulatory properties. Recent many studies reported that IL-33 is expressed in various organs and cells. Furthermore, IL-33 has been linked to many diseases, including rheumatoid arthritis, atopic dermatitis, asthma, pollinosis, atherosclerosis, cardiovascular diseases and autoimmune diseases.
Concentration:
1 mg/mL
Formulation:
1 mg/mL in PBS. Azide free, 0.22 um sterile-filtered Endotoxin level is <0.5 EU/mg antibody, as determined by the LAL assay
Gene IDs:
Mouse: 77125
Immunogen Translated:
Mouse IL-33, 109-266 aa (recombinant)
Shelf Life:
1 year
Source:
Purified IgG from hybridoma supernatant
Target:
IL-33

References

1) Ohno, T., et al., PLoS One 6, e18404 (2011) [Neutralization] 2) Matsuyama, Y., et al., J. Rheumatol. 37, 18-25 (2010) 3) Smith, D. E., et al., Clin. Exp. Allergy 40, 200-208 (2010) 4) Cayrol, C. and Girard, J. P., PNAS. 106, 9021-9026 (2009) 5) Luthi, A. U., et al., Immunity 31, 84-98 (2009) 6) Schmitz, J., et al., Immunity 23, 479-490 (2005)